KV Pharmaceutical
 
 
     
Research and Development
Makena Research®
SITE RELEASE®
KV’s SITE RELEASE® drug delivery system provides a creative, unique approach to drug delivery, combining bioadhesion to wet living tissues with controlled release of the drug agent. Products incorporating SITE RELEASE® technology are designed to adhere to wet living tissues, yet are minimally affected by the presence of moisture.

SITE RELEASE® is currently commercialized in two Ther-Rx Corporation products, Clindesse® (clindamycin phosphate) and Gynazole-1® (butoconazole nitrate), thus providing one-dose-to-treat products, with a potential to improve patient compliance, while also allowing anytime dosing with minimized leakage. SITE RELEASE® butoconazole nitrate 2% vaginal cream, used in Gyanazole-1® and clindamycin phosphate 2% vaginal cream used in Clindesse® have both received FDA approval.

Click here to review our Technology Evaluation: Advancing Vaginal Drug Delivery
site release

site release
Home | Contact Us | Site Directory | Legal/Privacy | Compliance Program ©2013 KV Pharmaceutical Company. All Rights Reserved.